Kraig Biocraft Laboratories reports recurring developments in recombinant spider silk technology, including production scale-up, new rearing capacity, cocoon output, and downstream reeling into usable silk fiber. The company’s technology is built around scientifically engineered silkworms that incorporate key spider silk proteins, with updates often tied to commercialization of materials for technical textiles, luxury wear, performance apparel, and other high-performance applications.
KBLB news also covers R&D execution, strain development, yield optimization, fiber performance, South East Asia production activity, and coordination with Prodigy Silk and related production networks.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced its preparation for a response to the U.S. Air Force under the Defense Production Act Investments program. This initiative aims to bolster U.S. bio-industrial manufacturing capabilities, specifically targeting materials like spider silk. Kraig Labs is set to submit its detailed response by April 19, 2023. While this does not guarantee funding or a proposal request, it signifies the growing interest in biomanufactured materials. COO Jon Rice expressed optimism about Kraig's role in enhancing domestic biomanufacturing and updating the DoD on its advancements.
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced the creation of two senior-level genetic engineering positions within its research and development team in the U.S. This expansion aims to enhance the team's capabilities, accelerating the development of spider silk technologies. The company expects these new roles will significantly increase research throughput, allowing for faster transition from concept to production for various spider silk protein designs. COO Jon Rice emphasized the potential for advancing new materials and transgenics in this exciting phase for the company.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) announced the delivery of the first two hybrid-cross Dragon Silk™ strains to its production partner in Vietnam. This development addresses key challenges in large-scale production, enhancing the robustness of silkworms. The new strains combine the mechanical performance of Dragon Silk with local silkworm traits, increasing cocoon size and resilience. Kraig Labs is also pursuing a four-line hybrid-cross program to further improve yields. COO Jon Rice highlighted the progress in overcoming production scaling challenges, signaling potential increases in production capacity and efficiency.